Skip to main content
Premium Trial:

Request an Annual Quote

Advaita, LifeMap Sign Software Marketing Agreement

NEW YORK (GenomeWeb) – Today, Advaita Bioinformatics announced a partnership with BioTime subsidiary LifeMap Sciences to promote and sell iPathwayGuide, Advaita's flagship genomic data analysis product.

Under the terms of the agreement, iPathwayGuide will be featured across several LifeMap products, including GeneCards, which is a reference database of human genes. Advaita's iPathway is a web-based application for analyzing information from next-generation sequencing and gene expression experiments and identifying the genetic pathways that are affected in disease. Customers of the solution are allowed to upload and analyze their data and view the results for free for 72 hours. They can then purchase a single report or pay a fee for unlimited access to the results.

The arrangement with LifeMap will "expose the usefulness and advance capabilities of iPathwayGuide to hundreds of thousands of LifeMaps’ users," Sorin Draghici, Advaita's president and CEO, said in a statement.  "We have already seen incredible interest [in] our software and this collaboration will continue to bring awareness of its advantages, as well as benefit the current LifeMap users."

The Scan

RNA Editing in Octopuses Seems to Help Acclimation to Shifts in Water Temperature

A paper in Cell reports that octopuses use RNA editing to help them adjust to different water temperatures.

Topical Compound to Block EGFR Inhibitors May Ease Skin Toxicities, Study Finds

A topical treatment described in Science Translational Medicine may limit skin toxicities seen with EGFR inhibitor therapy.

Dozen Genetic Loci Linked to Preeclampsia Risk in New GWAS

An analysis of genome-wide association study data in JAMA Cardiology finds genetic loci linked to preeclampsia that have ties to blood pressure.

Cancer Survival Linked to Mutational Burden in Pan-Cancer Analysis

A pan-cancer paper appearing in JCO Precision Oncology suggests tumor mutation patterns provide clues for predicting cancer survival that are independent of other prognostic factors.